Voriconazole News and Research

RSS
Voriconazole is a drug that treats infections caused by fungi.
Study presents rare cases of COVID-19-associated pulmonary aspergillosis

Study presents rare cases of COVID-19-associated pulmonary aspergillosis

Exploring remdesivir resistance in COVID-19-infected transplant recipients

Exploring remdesivir resistance in COVID-19-infected transplant recipients

High prevalence of fungal secondary infections among COVID-19 patients

High prevalence of fungal secondary infections among COVID-19 patients

Drug-resistant mold found to be spreading and infecting susceptible people's lungs

Drug-resistant mold found to be spreading and infecting susceptible people's lungs

New insights on how hospitalized patients develop liver injury from taking different drugs

New insights on how hospitalized patients develop liver injury from taking different drugs

Scientists develop new diagnostic procedure for pulmonary aspergillosis

Scientists develop new diagnostic procedure for pulmonary aspergillosis

FDA expands approval of Vertex' cystic fibrosis medicine to treat children aged 12 to <24 months

FDA expands approval of Vertex' cystic fibrosis medicine to treat children aged 12 to <24 months

New IDSA guidelines focus on diagnosis, treatment of deadly aspergillosis

New IDSA guidelines focus on diagnosis, treatment of deadly aspergillosis

Common drug used for treating fungal infections in lung transplant recipients increases risk for skin cancer, death

Common drug used for treating fungal infections in lung transplant recipients increases risk for skin cancer, death

Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Astellas' isavuconazole gets FDA orphan drug designation for treatment of invasive candidiasis

Astellas' isavuconazole gets FDA orphan drug designation for treatment of invasive candidiasis

Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

New antifungal drug effective against invasive mold disease in cancer patients with less adverse effects

New antifungal drug effective against invasive mold disease in cancer patients with less adverse effects

FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

Astellas seeks isavuconazole approval from FDA for treatment of life-threatening fungal infections

Astellas seeks isavuconazole approval from FDA for treatment of life-threatening fungal infections

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Astellas reports efficacy, safety data of isavuconazole invasive aspergillosis SECURE study at ECCMID

Astellas reports efficacy, safety data of isavuconazole invasive aspergillosis SECURE study at ECCMID

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

FDA grants QIDP status to Astellas' isavuconazole for treatment of invasive aspergillosis

FDA grants QIDP status to Astellas' isavuconazole for treatment of invasive aspergillosis